Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Certara and Veristat Expand Clinical Trial Service Offerings

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
Collaboration offers clients more streamlined and efficient approach to clinical trial planning.

Certara™ and Veristat, LLC. announced that they have formed an alliance to offer combined services to their clients. The joint service offering includes: Pharmacokinetic (PK) analysis, PK /Pharmacodynamic (PD) modeling, population PK modeling, trial simulation, clinical biostatistics, medical writing, data management, clinical monitoring, safety management, and project management. These combined services will help streamline the drug discovery, development and trial planning processes by improving the efficiency of data collection and analysis and enabling clients to procure value-added services through their existing vendor relationship.

“We look forward to offering Certara’s capabilities to our clients”

“We look forward to offering Certara’s capabilities to our clients,” said Patrick Flanagan, Chief Business Officer of Veristat. “Their Pharsight Consulting Services team is a world-class organization in the modeling and simulation of drugs and diseases. By combining our core services with their insight and experience, Veristat broadens our delivery platform and is able to more immediately respond to our clients’ outsourcing needs. The benefit to our clients is greater overall efficiency, impact and probability of success for their clinical trial programs.”

“We are pleased to partner with Veristat to expand what we can offer to clients as they seek to streamline their outsourcing of critical tasks in trial planning, analysis, and reporting,” said Daniel Weiner, Chief Technology Officer and head of Certara’s scientific consulting services. “Veristat specializes in several trial services that lie outside our core domain, and together we can offer more to the client than either organization could alone.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Simcyp Limited Acquired by Certara
The acquisition makes Simcyp the third member of the Certara group alongside Tripos and Pharsight.
Wednesday, March 07, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Genome of 6000-Year-Old Barley Sequenced
Researchers have successfully sequenced the genome of Chalcolithic barley grains for the first time.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!